<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MAXALT-MLT - rizatriptan benzoate tablet, orally disintegrating </strong><br><strong>MAXALT - rizatriptan benzoate tablet </strong><br>STAT RX USA LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_595baf7e-8ae6-445f-8cc4-82d8a94494ff"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MAXALT<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> contains rizatriptan benzoate, a selective 5-hydroxytryptamine<span class="Sub">1B/1D </span>(5-HT<span class="Sub">1B/1D</span>) receptor agonist.</p>
<p>Rizatriptan benzoate is described chemically as: <span class="Italics">N,N</span>-dimethyl-5-(1<span class="Italics">H</span>-1,2,4-triazol-1-ylmethyl)-1<span class="Italics">H</span>-indole-3-ethanamine monobenzoate and its structural formula is:</p>
<div class="Figure"><img alt="image of structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08d06e6f-a1d8-4bd9-b851-d63858d55f91&amp;name=580e55c2-f9b7-4212-98b7-cee54f55d309-01.jpg"></div>
<p>Its empirical formula is C<span class="Sub">15</span>H<span class="Sub">19</span>N<span class="Sub">5</span>•C<span class="Sub">7</span>H<span class="Sub">6</span>O<span class="Sub">2</span>, representing a molecular weight of the free base of 269.4. Rizatriptan benzoate is a white to off-white, crystalline solid that is soluble in water at about 42 mg per mL (expressed as free base) at 25°C.</p>
<p>MAXALT Tablets and MAXALT-MLT<a href="#footnote-1" class="Sup">1</a> Orally Disintegrating Tablets are available for oral administration in strengths of 5 and 10 mg (corresponding to 7.265 mg or 14.53 mg of the benzoate salt, respectively). Each compressed tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, pregelatinized starch, ferric oxide (red), and magnesium stearate.</p>
<p>Each lyophilized orally disintegrating tablet contains the following inactive ingredients: gelatin, mannitol, glycine, aspartame, and peppermint flavor.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd><p class="First">COPYRIGHT © 1998, 2006 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a29a4e3a-2798-4173-8eee-dd8f1b519bb6"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_6042e04c-26ac-4204-b8a5-0ef3d2cf0ba5"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Rizatriptan binds with high affinity to human cloned 5-HT<span class="Sub">1B</span> and 5-HT<span class="Sub">1D</span> receptors. Rizatriptan has weak affinity for other 5-HT<span class="Sub">1</span> receptor subtypes (5-HT<span class="Sub">1A</span>, 5-HT<span class="Sub">1E</span>, 5-HT<span class="Sub">1F</span>) and the 5-HT<span class="Sub">7</span> receptor, but has no significant activity at 5-HT<span class="Sub">2</span>, 5-HT<span class="Sub">3</span>, alpha- and beta-adrenergic, dopaminergic, histaminergic, muscarinic or benzodiazepine receptors. </p>
<p>Current theories on the etiology of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> suggest that symptoms are due to local cranial <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and/or to the release of vasoactive and pro-inflammatory peptides from sensory nerve endings in an activated trigeminal system. The therapeutic activity of rizatriptan in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> can most likely be attributed to agonist effects at 5-HT<span class="Sub">1B/1D</span> receptors on the extracerebral, intracranial blood vessels that become dilated during a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack and on nerve terminals in the trigeminal system. Activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> pathways. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_cf503bf4-20ed-4668-9e59-032d6348028d"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Rizatriptan is completely absorbed following oral administration. The mean oral absolute bioavailability of the MAXALT Tablet is about 45%, and mean peak plasma concentrations (C<span class="Sub">max</span>) are reached in approximately 1-1.5 hours (T<span class="Sub">max</span>). The presence of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> did not appear to affect the absorption or pharmacokinetics of rizatriptan. Food has no significant effect on the bioavailability of rizatriptan but delays the time to reach peak concentration by an hour. In clinical trials, MAXALT was administered without regard to food. The plasma half-life of rizatriptan in males and females averages 2-3 hours.</p>
<p>The bioavailability and C<span class="Sub">max</span> of rizatriptan were similar following administration of MAXALT Tablets and MAXALT-MLT Orally Disintegrating Tablets, but the rate of absorption is somewhat slower with MAXALT-MLT, with T<span class="Sub">max</span> averaging 1.6-2.5 hours. AUC of rizatriptan is approximately 30% higher in females than in males. No accumulation occurred on multiple dosing.</p>
<p>The mean volume of distribution is approximately 140 liters in male subjects and 110 liters in female subjects. Rizatriptan is minimally bound (14%) to plasma proteins.</p>
<p>The primary route of rizatriptan metabolism is via oxidative deamination by monoamine oxidase-A (MAO-A) to the indole acetic acid metabolite, which is not active at the 5-HT<span class="Sub">1B/1D</span> receptor. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT<span class="Sub">1B/1D</span> receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT<span class="Sub">1B/1D</span> receptor.</p>
<p>The total radioactivity of the administered dose recovered over 120 hours in urine and feces was 82% and 12%, respectively, following a single 10 mg oral administration of <span class="Sup">14</span>C-rizatriptan. Following oral administration of <span class="Sup">14</span>C-rizatriptan, rizatriptan accounted for about 17% of circulating plasma radioactivity. Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism.</p>
<p><span class="Italics">Cytochrome P450 Isoforms:</span> Rizatriptan is not an inhibitor of the activities of human liver cytochrome P450 isoforms 3A4/5, 1A2, 2C9, 2C19, or 2E1; rizatriptan is a competitive inhibitor (Ki=1400 nM) of cytochrome P450 2D6, but only at high, clinically irrelevant concentrations.</p>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_6d46c562-e5e4-4bcb-85a5-2d33fd91a204"></a><a name="section-2.2.1"></a><p></p>
<h3>Special Populations</h3>
<p class="First"><span class="Italics">Age:</span> Rizatriptan pharmacokinetics in healthy elderly non-migraineur volunteers (age 65-77 years) were similar to those in younger non-migraineur volunteers (age 18-45 years).</p>
<p><span class="Italics">Gender:</span> The mean AUC<span class="Sub">0-∞</span> and C<span class="Sub">max</span> of rizatriptan (10 mg orally) were about 30% and 11% higher in females as compared to males, respectively, while T<span class="Sub">max</span> occurred at approximately the same time.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> Following oral administration in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> caused by mild to moderate <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> of the liver, plasma concentrations of rizatriptan were similar in patients with mild <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> compared to a control group of healthy subjects; plasma concentrations of rizatriptan were approximately 30% greater in patients with moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. (See <a href="#i4i_precautions_id_53d97911-bf99-4ad9-8802-b562807731da">PRECAUTIONS</a>.)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 10-60 mL/min/1.73 m<span class="Sup">2</span>), the AUC<span class="Sub">0-∞</span> of rizatriptan was not significantly different from that in healthy subjects. In hemodialysis patients, (creatinine clearance &lt; 2 mL/min/1.73 m<span class="Sup">2</span>), however, the AUC for rizatriptan was approximately 44% greater than that in patients with normal renal function. (See <a href="#i4i_precautions_id_53d97911-bf99-4ad9-8802-b562807731da">PRECAUTIONS</a>.)</p>
<p><span class="Italics">Race:</span> Pharmacokinetic data revealed no significant differences between African American and Caucasian subjects.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_6844830e-902b-4e62-b431-e118c961e6c8"></a><a name="section-2.2.2"></a><p></p>
<h3>Drug Interactions</h3>
<p class="First">(See also <a href="#i4i_interactions_id_c60133da-7e81-455d-94de-a3419361e10e">PRECAUTIONS, Drug Interactions</a>.)</p>
<p><span class="Italics">Monoamine oxidase inhibitors:</span> Rizatriptan is principally metabolized via monoamine oxidase, ‘A’ subtype (MAO-A). Plasma concentrations of rizatriptan may be increased by drugs that are selective MAO-A inhibitors (e.g., moclobemide) or nonselective MAO inhibitors [type A and B] (e.g., isocarboxazid, phenelzine, tranylcypromine, and pargyline). In a drug interaction study, when MAXALT 10 mg was administered to subjects (n=12) receiving concomitant therapy with the selective, reversible MAO-A inhibitor, moclobemide 150 mg t.i.d., there were mean increases in rizatriptan AUC and C<span class="Sub">max</span> of 119% and 41% respectively; and the AUC of the active N-monodesmethyl metabolite of rizatriptan was increased more than 400%. The interaction would be expected to be greater with irreversible MAO inhibitors. No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> is anticipated in patients receiving selective MAO-B inhibitors. (See <a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a>; <a href="#i4i_interactions_id_c60133da-7e81-455d-94de-a3419361e10e">PRECAUTIONS, Drug Interactions</a>.)</p>
<p><span class="Italics">Propranolol: </span> In a study of concurrent administration of propranolol 240 mg/day and a single dose of rizatriptan 10 mg in healthy subjects (n=11), mean plasma AUC for rizatriptan was increased by 70% during propranolol administration, and a fourfold increase was observed in one subject. The AUC of the active N-monodesmethyl metabolite of rizatriptan was not affected by propranolol. (See <a href="#i4i_precautions_id_53d97911-bf99-4ad9-8802-b562807731da">PRECAUTIONS</a>; <a href="#i4i_dosage_admin_id_5aa65e3b-f4cb-47ac-abca-65cf9d79fa26">DOSAGE AND ADMINISTRATION</a>.)</p>
<p><span class="Italics">Nadolol/Metoprolol: </span> In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed.</p>
<p><span class="Italics">Paroxetine:</span> In a study of the interaction between the selective serotonin reuptake inhibitor (SSRI) paroxetine 20 mg/day for two weeks and a single dose of MAXALT 10 mg in healthy subjects (n=12), neither the plasma concentrations of rizatriptan nor its safety profile were affected by paroxetine (see <a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a> and <a href="#i4i_info_patients_id_fc216a8a-66fe-4332-8c20-fe59b550cd29">PRECAUTIONS, Information for Patients</a>).</p>
<p><span class="Italics">Oral contraceptives:</span> In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_53ad93f4-847e-43d7-9bfc-74aa3ebd856c"></a><a name="section-2.3"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">The efficacy of MAXALT Tablets was established in four multicenter, randomized, placebo-controlled trials. Patients enrolled in these studies were primarily female (84%) and Caucasian (88%), with a mean age of 40 years (range of 18 to 71). Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response, defined as a reduction of moderate or severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to no or mild <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was assessed for up to 2 hours (Study 1) or up to 4 hours after dosing (Studies 2, 3 and 4). Associated symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> and maintenance of response up to 24 hours postdose were evaluated. A second dose of MAXALT Tablets was allowed 2 to 24 hours after dosing for treatment of recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> in Studies 1 and 2. Additional analgesics and/or antiemetics were allowed 2 hours after initial treatment for rescue in all four studies.</p>
<p>In all studies, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 2 hours after treatment was significantly greater in patients who received either MAXALT 5 or 10 mg compared to those who received placebo. In a separate study, doses of 2.5 mg were not different from placebo. Doses greater than 10 mg were associated with an increased incidence of adverse effects. The results from the 4 controlled studies using the marketed formulation are summarized in Table 1.</p>
<a name="id_4f959ac3-1aa5-49c7-bb85-b1c8f263d177"></a><table width="571.000">
<caption><span>Table 1: Response Rates 2 Hours Following Treatment of Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></caption>
<col width="22.1%">
<col width="20.1%">
<col width="20.1%">
<col width="37.7%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top">Study</td>
<td class="Botrule" align="center" valign="top">Placebo</td>
<td class="Botrule" align="center" valign="top">MAXALT Tablets<br>5 mg</td>
<td class="Botrule" align="center" valign="top">MAXALT Tablets<br>10 mg</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>p value &lt; 0.05 in comparison with placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="center" valign="top"> 1</td>
<td class="Toprule" align="center" valign="top">35% (n=304)</td>
<td class="Toprule" align="center" valign="top">62%<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> (n=458)</td>
<td align="center" valign="top">71%<a href="#footnote-2" class="Sup">*</a><span class="Sup">,</span>
                                     (n=456)</td>
</tr>
<tr>
<td align="center" valign="top"> 2
                                 </td>
<td align="center" valign="top">37% (n=82)</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">77%<a href="#footnote-2" class="Sup">*</a> (n=320)</td>
</tr>
<tr>
<td align="center" valign="top"> 3</td>
<td align="center" valign="top">23% (n=80)</td>
<td align="center" valign="top">63%<a href="#footnote-2" class="Sup">*</a> (n=352)</td>
<td align="center" valign="top">—</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top"> 4</td>
<td class="Botrule" align="center" valign="top">40% (n=159)</td>
<td class="Botrule" align="center" valign="top">60%<a href="#footnote-2" class="Sup">*</a> (n=164)</td>
<td class="Botrule" align="center" valign="top">67%<a href="#footnote-2" class="Sup">*</a> (n=385)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Comparisons of drug performance based upon results obtained in different clinical trials are never reliable. Because studies are conducted at different times, with different samples of patients, by different investigators, employing different criteria and/or different interpretations of the same criteria, under different conditions (dose, dosing regimen, etc.), quantitative estimates of treatment response and the timing of response may be expected to vary considerably from study to study.</span></p>
<p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response within 2 hours following treatment is depicted in Figure 1.</p>
<div class="Figure">
<img alt="image of Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08d06e6f-a1d8-4bd9-b851-d63858d55f91&amp;name=580e55c2-f9b7-4212-98b7-cee54f55d309-02.jpg"><p class="MultiMediaCaption">Figure 1: Estimated Probability of Achieving an Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response by 2 Hours<span class="Sup">††</span></p>
</div>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> at baseline, there was a decreased incidence of these symptoms following administration of MAXALT compared to placebo.</p>
<p>Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response in the form of a second dose of study treatment or other medication. The estimated probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 2.</p>
<div class="Figure">
<img alt="image of Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08d06e6f-a1d8-4bd9-b851-d63858d55f91&amp;name=580e55c2-f9b7-4212-98b7-cee54f55d309-03.jpg"><p class="MultiMediaCaption">Figure 2: Estimated Probability of Patients Taking a Second Dose of MAXALT Tablets or Other Medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> Over the 24 Hours Following the Initial Dose of Study Treatment<span class="Sup">†††</span></p>
</div>
<p>Efficacy was unaffected by the presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>; by the gender, or age of the patient; or by concomitant use of common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs (e.g., beta-blockers, calcium channel blockers, tricyclic antidepressants) or oral contraceptives. In two additional similar studies, efficacy was unaffected by relationship to menses. There were insufficient data to assess the impact of race on efficacy.</p>
<p>In a single study in adolescents (n=291), there were no statistically significant differences between treatment groups. The <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response rates at 2 hours were 66% and 56% for MAXALT 5 mg Tablets and placebo, respectively.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ee7792e-e0c3-4754-9320-66aa9a289431"></a><a name="section-2.3.1"></a><p></p>
<h3>MAXALT-MLT Orally Disintegrating Tablets</h3>
<p class="First">The efficacy of MAXALT-MLT was established in two multicenter, randomized, placebo-controlled trials that were similar in design to the trials of MAXALT Tablets. Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Patients treated in these studies were primarily female (88%) and Caucasian (95%), with a mean age of 42 years (range 18-72).</p>
<p>In both studies, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 2 hours after treatment was significantly greater in patients who received either MAXALT-MLT 5 or 10 mg compared to those who received placebo. The results from the 2 controlled studies using the marketed formulation are summarized in Table 2.</p>
<a name="id_396ddd8f-3e4d-4e67-af65-06af4a31c664"></a><table width="577.000">
<caption><span>Table 2: Response Rates 2 Hours Following Treatment of Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></caption>
<col width="21.0%">
<col width="19.9%">
<col width="26.7%">
<col width="32.4%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top">Study</td>
<td class="Botrule" align="center" valign="top">Placebo</td>
<td class="Botrule" align="center" valign="top">MAXALT-MLT<br>5 mg</td>
<td class="Botrule" align="center" valign="top">MAXALT-MLT<br>10 mg</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>p value &lt; 0.01 in comparison with placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="center" valign="top">1</td>
<td class="Toprule" align="center" valign="top">47% (n=98)</td>
<td class="Toprule" align="center" valign="top">66%<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> (n=100)</td>
<td align="center" valign="top">66%<a href="#footnote-3" class="Sup">*</a> (n=113)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">28% (n=180)</td>
<td class="Botrule" align="center" valign="top">59%<a href="#footnote-3" class="Sup">*</a> (n=181)</td>
<td class="Botrule" align="center" valign="top">74%<a href="#footnote-3" class="Sup">*</a><span class="Sup">,</span>
                                           (n=186)</td>
</tr>
</tbody>
</table>
<p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response by 2 hours following treatment with MAXALT-MLT is depicted in Figure 3.</p>
<div class="Figure">
<img alt="image of Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08d06e6f-a1d8-4bd9-b851-d63858d55f91&amp;name=580e55c2-f9b7-4212-98b7-cee54f55d309-04.jpg"><p class="MultiMediaCaption">Figure 3: Estimated Probability of Achieving an Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response with MAXALT-MLT by 2 Hours<span class="Sup">‡</span></p>
</div>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> at baseline, there was a decreased incidence of these symptoms following administration of MAXALT-MLT as compared to placebo.</p>
<p>Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response in the form of a second dose of study treatment or other medication. The estimated probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 4.</p>
<div class="Figure">
<img alt="image of Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08d06e6f-a1d8-4bd9-b851-d63858d55f91&amp;name=580e55c2-f9b7-4212-98b7-cee54f55d309-05.jpg"><p class="MultiMediaCaption">Figure 4: Estimated Probability of Patients Taking a Second Dose of MAXALT-MLT or Other Medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> Over the 24 Hours Following the Initial Dose of Study Treatment<span class="Sup">‡‡</span></p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_99064215-3423-431a-8b37-ff4bcf2f24a6"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">MAXALT is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<p>MAXALT is not intended for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or for use in the management of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (see <a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a>). Safety and effectiveness of MAXALT have not been established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>, which is present in an older, predominantly male population.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">MAXALT should not be given to patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>) or to patients who have symptoms or findings consistent with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, including Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>, or other significant underlying cardiovascular disease (see </span><a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a><span class="Bold">). </span></p>
<p><span class="Bold">Because MAXALT may increase blood pressure, it should not be given to patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> (see </span><a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a><span class="Bold">). </span></p>
<p><span class="Bold">MAXALT should not be used within 24 hours of treatment with another 5-HT<span class="Sub">1</span> agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide.</span></p>
<p><span class="Bold">MAXALT should not be administered to patients with hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. </span></p>
<p><span class="Bold">Concurrent administration of MAO inhibitors or use of rizatriptan within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated (see </span><a href="#i4i_interactions_id_6844830e-902b-4e62-b431-e118c961e6c8">CLINICAL PHARMACOLOGY, Drug Interactions</a><span class="Bold"> and </span><a href="#i4i_interactions_id_c60133da-7e81-455d-94de-a3419361e10e">PRECAUTIONS, Drug Interactions</a><span class="Bold">).</span></p>
<p><span class="Bold">MAXALT is contraindicated in patients who are hypersensitive to rizatriptan or any of its inactive ingredients.</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">MAXALT should only be used where a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established. </span></p>
<p><span class="Bold"><span class="Italics">Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events: </span></span><span class="Bold"> Because of the potential of this class of compounds (5-HT<span class="Sub">1B/1D</span> agonists) to cause <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>, MAXALT should not be given to patients with documented ischemic or vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (see </span><a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a><span class="Bold">). It is strongly recommended that rizatriptan not be given to patients in whom unrecognized <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) is predicted by the presence of risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, smoker, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, strong family history of CAD, female with surgical or physiological <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, or male over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> is modest, at best. If, during the cardiovascular evaluation, the patient’s medical history, electrocardiographic or other investigations reveal findings indicative of, or consistent with, coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, rizatriptan should not be administered (see </span><a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a><span class="Bold">). </span></p>
<p><span class="Bold">For patients with risk factors predictive of CAD, who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of rizatriptan take place in the setting of a physician’s office or similar medically staffed and equipped facility unless the patient has previously received rizatriptan. Because <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span> can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following MAXALT, in these patients with risk factors.</span></p>
<p><span class="Bold">It is recommended that patients who are intermittent long-term users of MAXALT and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use MAXALT. </span></p>
<p><span class="Bold">The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to rizatriptan.</span></p>
<p><span class="Italics">Cardiac Events and Fatalities Associated with 5-HT<span class="Sub">1</span> Agonists:</span> Serious adverse cardiac events, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, have been reported within a few hours following the administration of rizatriptan. Life-threatening disturbances of cardiac rhythm and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported within a few hours following the administration of other 5-HT<span class="Sub">1</span> agonists. Considering the extent of use of 5-HT<span class="Sub">1</span> agonists in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, the incidence of these events is extremely low. MAXALT can cause <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>. Because of the close proximity of the events to MAXALT use, a causal relationship cannot be excluded. In the cases where there has been known underlying <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, the relationship is uncertain.</p>
<p><span class="Italics">Premarketing experience with rizatriptan:</span> Among the 3700 patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> who participated in premarketing clinical trials of MAXALT, one patient was reported to have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> with possible ischemic ECG changes following a single dose of 10 mg.</p>
<p><span class="Italics">Postmarketing experience with rizatriptan:</span> Serious cardiovascular events have been reported in association with the use of MAXALT. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to determine definitively the proportion of the reported cases that were actually caused by rizatriptan or to reliably assess causation in individual cases.</p>
<p><span class="Italics">Cerebrovascular Events and Fatalities Associated with 5-HT<span class="Sub">1</span> Agonists:</span> <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and other cerebrovascular events have been reported in patients treated with 5-HT<span class="Sub">1</span> agonists; and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, when they were not. It should be noted that patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, transient ischemic attack).</p>
<p><span class="Italics">Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events:</span> 5-HT<span class="Sub">1</span> agonists may cause vasospastic reactions other than coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>. Both peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and colonic <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> have been reported with 5-HT<span class="Sub">1</span> agonists.</p>
<p><span class="Italics">Increase in Blood Pressure:</span> Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, has been reported on rare occasions in patients receiving 5-HT<span class="Sub">1</span> agonists with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. In healthy young male and female subjects who received maximal doses of MAXALT (10 mg every 2 hours for 3 doses), slight increases in blood pressure (approximately 2-3 mmHg) were observed. Rizatriptan is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> (see <a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a>). </p>
<p>An 18% increase in mean pulmonary artery pressure was seen following dosing with another 5-HT<span class="Sub">1</span> agonist in a study evaluating subjects undergoing cardiac catheterization.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>:</span> The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may occur with triptans, including MAXALT treatment, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If concomitant treatment with rizatriptan and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) (see <a href="#i4i_interactions_id_c60133da-7e81-455d-94de-a3419361e10e">PRECAUTIONS, Drug Interactions</a>). </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_53d97911-bf99-4ad9-8802-b562807731da"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_aa5393d2-d5f3-4082-bc28-9fbaf2ade0bd"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with other 5-HT<span class="Sub">1B/1D</span> agonists, sensations of tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, and heaviness have been reported after treatment with MAXALT in the precordium, throat, neck and jaw. These events have not been associated with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or definite ischemic ECG changes in clinical trials (one patient experienced <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> with possible ischemic ECG changes). Because drugs in this class may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of CAD or a predisposition to Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud’s syndrome following the use of any 5-HT<span class="Sub">1</span> agonist are candidates for further evaluation (see <a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a>).</p>
<p>Rizatriptan should also be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs (see <a href="#i4i_specific_populations_id_6d46c562-e5e4-4bcb-85a5-2d33fd91a204">CLINICAL PHARMACOLOGY, Special Populations</a>).</p>
<p><span class="Italics">Renally Impaired Patients:</span> Rizatriptan should be used with caution in dialysis patients due to a decrease in the clearance of rizatriptan (see <a href="#i4i_specific_populations_id_6d46c562-e5e4-4bcb-85a5-2d33fd91a204">CLINICAL PHARMACOLOGY, Special Populations</a>).</p>
<p><span class="Italics">Hepatically Impaired Patients: </span>Rizatriptan should be used with caution in patients with moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> due to an increase in plasma concentrations of approximately 30% (see <a href="#i4i_specific_populations_id_6d46c562-e5e4-4bcb-85a5-2d33fd91a204">CLINICAL PHARMACOLOGY, Special Populations</a>).</p>
<p>For a given attack, if a patient has no response to the first dose of rizatriptan, the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> should be reconsidered before administration of a second dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc60b335-3fb6-4a2b-a7fb-707913bdca2e"></a><a name="section-6.2"></a><p></p>
<h2>Binding to Melanin-Containing Tissues</h2>
<p class="First">The propensity for rizatriptan to bind melanin has not been investigated. Based on its chemical properties, rizatriptan may bind to melanin and accumulate in melanin rich tissue (e.g., eye) over time. This raises the possibility that rizatriptan could cause toxicity in these tissues after extended use. There were, however, no adverse ophthalmologic changes related to treatment with rizatriptan in the one year dog toxicity study. Although no systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long-term ophthalmologic effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aec69500-37ab-4003-bcfb-225431823378"></a><a name="section-6.3"></a><p></p>
<h2>Phenylketonurics</h2>
<p class="First">Phenylketonuric patients should be informed that MAXALT-MLT Orally Disintegrating Tablets contain phenylalanine (a component of aspartame). Each 5-mg orally disintegrating tablet contains 1.05 mg phenylalanine, and each 10-mg orally disintegrating tablet contains 2.10 mg phenylalanine.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_fc216a8a-66fe-4332-8c20-fe59b550cd29"></a><a name="section-6.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> or treatment with MAXALT may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> in some patients. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> has also been reported in some patients receiving MAXALT. Patients should, therefore, evaluate their ability to perform complex tasks during <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks and after administration of MAXALT.</p>
<p>Physicians should instruct their patients to read the patient package insert before taking MAXALT. See the accompanying <a href="#i4i_patient_package_insert_id_4ab8ff74-3f55-4cf8-91b2-496663986002">PATIENT INFORMATION</a> leaflet.</p>
<p>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of rizatriptan or other triptans, especially during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) (see <a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_447d3c45-8006-49c1-85fc-3c02dc08cc67"></a><a name="section-6.5"></a><p></p>
<h2>MAXALT-MLT Orally Disintegrating Tablets</h2>
<p class="First">Patients should be instructed not to remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the outer pouch until just prior to dosing. The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack should then be peeled open with dry hands and the orally disintegrating tablet placed on the tongue, where it will dissolve and be swallowed with the saliva.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_3505804a-ba36-462e-bb0f-4bb17c879920"></a><a name="section-6.6"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">No specific laboratory tests are recommended for monitoring patients prior to and/or after treatment with MAXALT.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_c60133da-7e81-455d-94de-a3419361e10e"></a><a name="section-6.7"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">(See also <a href="#i4i_interactions_id_6844830e-902b-4e62-b431-e118c961e6c8">CLINICAL PHARMACOLOGY, Drug Interactions</a>.)</p>
<p><span class="Italics">Propranolol:</span> Rizatriptan 5 mg should be used in patients taking propranolol, as propranolol has been shown to increase the plasma concentrations of rizatriptan by 70% (see <a href="#i4i_interactions_id_6844830e-902b-4e62-b431-e118c961e6c8">CLINICAL PHARMACOLOGY, Drug Interactions</a>; <a href="#i4i_dosage_admin_id_5aa65e3b-f4cb-47ac-abca-65cf9d79fa26">DOSAGE AND ADMINISTRATION</a>).</p>
<p><span class="Italics">Ergot-containing drugs:</span> Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and rizatriptan within 24 hours is contraindicated (see <a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a>).</p>
<p><span class="Italics">Other 5-HT<span class="Sub">1</span> agonists: </span> The administration of rizatriptan with other 5-HT<span class="Sub">1</span> agonists has not been evaluated in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients. Because their vasospastic effects may be additive, coadministration of rizatriptan and other 5-HT<span class="Sub">1</span> agonists within 24 hours of each other is not recommended (see <a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a>).</p>
<p><span class="Italics">Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>:</span> Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans (see <a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a>).</p>
<p><span class="Italics">Monoamine oxidase inhibitors: </span> Rizatriptan should not be administered to patients taking MAO-A inhibitors and non-selective MAO inhibitors; it has been shown that moclobemide (a specific MAO-A inhibitor) increased the systemic exposure of rizatriptan and its metabolite (see <a href="#i4i_interactions_id_6844830e-902b-4e62-b431-e118c961e6c8">CLINICAL PHARMACOLOGY, Drug Interactions</a>; <a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_8808b538-dba9-4ec1-a20e-e6ef7d1fd8b8"></a><a name="section-6.8"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">MAXALT is not known to interfere with commonly employed clinical laboratory tests.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_dcebc2a1-c67a-4656-a528-922b65d98610"></a><a name="section-6.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis:</span> The lifetime carcinogenic potential of rizatriptan was evaluated in a 100-week study in mice and a 106-week study in rats at oral gavage doses of up to 125 mg/kg/day. Exposure data were not obtained in those studies, but plasma AUC’s of parent drug measured in other studies after 5 and 21 weeks of oral dosing in mice and rats, respectively, indicate that the exposures to parent drug at the highest dose level in the carcinogenicity studies would have been approximately 150 times (mice) and 240 times (rats) average AUC’s measured in humans after three 10 mg doses, the maximum recommended total daily dose. There was no evidence of an increase in tumor incidence related to rizatriptan in either species.</p>
<p><span class="Italics">Mutagenesis: </span>Rizatriptan, with and without metabolic activation, was neither mutagenic, nor clastogenic in a battery of <span class="Italics">in vitro</span> and<span class="Italics"> in vivo</span> genetic toxicity studies, including: the microbial mutagenesis (Ames) assay, the <span class="Italics">in vitro</span> mammalian cell mutagenesis assay in V-79 Chinese hamster lung cells, the <span class="Italics">in vitro </span> alkaline elution assay in rat hepatocytes, the <span class="Italics">in vitro</span> chromosomal aberration assay in Chinese hamster ovary cells and the <span class="Italics">in vivo</span> chromosomal aberration assay in mouse bone marrow.</p>
<p><span class="Italics">Impairment of Fertility:</span> In a fertility study in rats, altered estrus cyclicity and delays in time to mating were observed in females treated orally with 100 mg/kg/day rizatriptan. Plasma drug exposure (AUC) at this dose was approximately 225 times the exposure in humans receiving the maximum recommended daily dose (MRDD) of 30 mg. The no-effect dose was 10 mg/kg/day (approximately 15 times the human exposure at the MRDD). There were no other fertility-related effects in the female rats. There was no impairment of fertility or reproductive performance in male rats treated with up to 250 mg/kg/day (approximately 550 times the human exposure at the MRDD).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_f581228b-7bfe-4434-8405-9604a24666e2"></a><a name="section-6.10"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b8ec9ef-1217-4927-9128-e19630e1765f"></a><a name="section-6.10.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">In a general reproductive study in rats, birth weights and pre- and post-weaning <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were reduced in the offspring of females treated prior to and during mating and throughout gestation and lactation with doses of 10 and 100 mg/kg/day. Maternal drug exposures (AUC) at these doses were approximately 15 and 225 times, respectively, the exposure in humans receiving the maximum recommended daily dose (MRDD) of 30 mg. In a pre- and post-natal developmental toxicity study in rats, an increase in mortality of the offspring at birth and for the first three days after birth, a decrease in pre- and post-weaning <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and decreased performance in a passive avoidance test (which indicates a decrease in learning capacity of the offspring) were observed at doses of 100 and 250 mg/kg/day. The no-effect dose for all of these effects was 5 mg/kg/day, approximately 7.5 times the exposure in humans receiving the MRDD. With doses of 100 and 250 mg/kg/day, the decreases in average weight of both the male and female offspring persisted into adulthood. All of these effects on the offspring in both reproductive toxicity studies occurred in the absence of any apparent maternal toxicity.</p>
<p>In embryofetal development studies, no teratogenic effects were observed when pregnant rats and rabbits were administered doses of 100 and 50 mg/kg/day, respectively, during organogenesis. Fetal weights were decreased in conjunction with decreased maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> at the highest doses (maternal exposures approximately 225 and 115 times the human exposure at the MRDD in rats and rabbits, respectively). The developmental no-effect dose in these studies was 10 mg/kg/day in both rats and rabbits (maternal exposures approximately 15 times human exposure at the MRDD). Toxicokinetic studies demonstrated placental transfer of drug in both species.</p>
<p>There are no adequate and well-controlled studies in pregnant women; therefore, rizatriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., maintains a registry to monitor the pregnancy outcomes of women exposed to MAXALT while pregnant. Healthcare providers are encouraged to report any prenatal exposure to MAXALT by calling the Pregnancy Registry at (800) 986-8999.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_11c33c43-9f9a-4564-b3fd-a6927061ae25"></a><a name="section-6.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXALT is administered to women who are breast-feeding. Rizatriptan is extensively excreted in rat milk, at a level of 5-fold or greater than maternal plasma levels.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_686e0f2e-ca1a-4b56-baba-818590c09751"></a><a name="section-6.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of rizatriptan in pediatric patients have not been established; therefore, MAXALT is not recommended for use in patients under 18 years of age.</p>
<p>The efficacy of MAXALT Tablets (5 mg) in patients aged 12 to 17 years was not established in a randomized placebo-controlled trial of 291 adolescent migraineurs (see <a href="#i4i_clinical_studies_id_53ad93f4-847e-43d7-9bfc-74aa3ebd856c">Clinical Studies</a>). Adverse events observed were similar in nature to those reported in clinical trials in adults. Postmarketing experience with other triptans includes a limited number of reports that describe pediatric patients who have experienced clinically serious adverse events that are similar in nature to those reported rarely in adults. The long-term safety of rizatriptan in pediatric patients has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9bd33f19-1384-4c31-8c5b-2e18068316c5"></a><a name="section-6.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">The pharmacokinetics of rizatriptan were similar in elderly (aged ≥ 65 years) and in younger adults. Because <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> occurs infrequently in the elderly, clinical experience with MAXALT is limited in such patients. In clinical trials, there were no apparent differences in efficacy or in overall adverse experience rates between patients under 65 years of age and those 65 and above (n=17).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_80e9a2ad-9cb7-4d81-b9e2-29da5201b1af"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Serious cardiac events, including some that have been fatal, have occurred following use of 5-HT<span class="Sub">1</span> agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, transient <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> (see </span><a href="#i4i_contraindications_id_39a0f524-90ca-4fc8-8089-f91b3e882d0d">CONTRAINDICATIONS</a><span class="Bold">, </span><a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a><span class="Bold">, and </span><a href="#i4i_precautions_id_53d97911-bf99-4ad9-8802-b562807731da">PRECAUTIONS</a><span class="Bold">).</span></p>
<p><span class="Italics">Incidence in Controlled Clinical Trials:</span> Adverse experiences to rizatriptan were assessed in controlled clinical trials that included over 3700 patients who received single or multiple doses of MAXALT Tablets. The most common adverse events during treatment with MAXALT were <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/pressure sensation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. These events appeared to be dose related. In long term extension studies where patients were allowed to treat multiple attacks for up to 1 year, 4% (59 out of 1525 patients) withdrew because of adverse experiences.</p>
<p>Table 3 lists the adverse events regardless of drug relationship (incidence ≥ 2% and greater than placebo) after a single dose of MAXALT. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.</p>
<a name="id_33f17d44-5a12-451c-8b7c-1648c9196d8d"></a><table width="652.000">
<caption><span>Table 3: Incidence (≥ 2% and Greater than Placebo) of Adverse Experiences After a Single Dose of MAXALT Tablets or Placebo</span></caption>
<col width="42.9%">
<col width="19.0%">
<col width="19.0%">
<col width="19.0%">
<thead>
<tr class="First">
<td class="Toprule" align="center" valign="top"> </td>
<td class="Botrule" align="center" colspan="3" valign="top">% of Patients</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">
<br>Adverse Experiences</td>
<td class="Botrule" align="center" valign="top">MAXALT<br>5 mg<br>(N=977)</td>
<td class="Botrule" align="center" valign="top">MAXALT<br>10 mg<br>(N=1167)</td>
<td class="Botrule" align="center" valign="top">
<br>Placebo<br>(N=627)</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Italics">Atypical Sensations </span></td>
<td class="Toprule" align="center" valign="top">4</td>
<td class="Toprule" align="center" valign="top">5</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">&lt;2</td>
</tr>
<tr>
<td align="left" valign="top">
<br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and other Pressure Sensations</span>
</td>
<td align="center" valign="bottom">6</td>
<td align="center" valign="bottom">9</td>
<td align="center" valign="bottom">3</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span>:<br>        tightness/pressure and/or heaviness</td>
<td align="center" valign="bottom">&lt;2</td>
<td align="center" valign="bottom">3</td>
<td align="center" valign="bottom">1</td>
</tr>
<tr>
<td align="left" valign="top">    Neck/throat/jaw:<br>        <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/tightness/pressure</td>
<td align="center" valign="bottom">&lt;2</td>
<td align="center" valign="bottom">2</td>
<td align="center" valign="bottom">1</td>
</tr>
<tr>
<td align="left" valign="top">    Regional <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>: <br>        tightness/pressure/heaviness</td>
<td align="center" valign="bottom">&lt;1</td>
<td align="center" valign="bottom">2</td>
<td align="center" valign="bottom">0</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, location unspecified</td>
<td align="center" valign="bottom">3</td>
<td align="center" valign="bottom">3</td>
<td align="center" valign="bottom">&lt;2</td>
</tr>
<tr>
<td align="left" valign="top">
<br><span class="Italics">Digestive</span>
</td>
<td align="center" valign="bottom">9</td>
<td align="center" valign="bottom">13</td>
<td align="center" valign="bottom">8</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">
<br><span class="Italics">Neurological </span>
</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom">11</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">5</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">&lt;2</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">4</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">
<br><span class="Italics">Other</span><br>    <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></td>
<td class="Botrule" align="center" valign="bottom">4</td>
<td class="Botrule" align="center" valign="bottom">7</td>
<td class="Botrule" align="center" valign="bottom">2</td>
</tr>
</tbody>
</table>
<p>MAXALT was generally well-tolerated. Adverse experiences were typically mild in intensity and were transient. The frequencies of adverse experiences in clinical trials did not increase when up to three doses were taken within 24 hours. Adverse event frequencies were also unchanged by concomitant use of drugs commonly taken for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis (including propranolol), oral contraceptives, or analgesics. The incidences of adverse experiences were not affected by age or gender. There were insufficient data to assess the impact of race on the incidence of adverse events.</p>
<p><span class="Italics">Other Events Observed in Association with the Administration of MAXALT:</span> In the section that follows, the frequencies of less commonly reported adverse clinical events are presented. Because the reports include events observed in open studies, the role of MAXALT in their causation cannot be reliably determined. Furthermore, variability associated with adverse event reporting, the terminology used to describe adverse events, etc., limit the value of the quantitative frequency estimates provided. Event frequencies are calculated as the number of patients who used MAXALT (N=3716) and reported an event divided by the total number of patients exposed to MAXALT. All reported events are included, except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are those defined as those occurring in at least (&gt;)1/100 patients; infrequent adverse experiences are those occurring in 1/100 to 1/1000 patients; and rare adverse experiences are those occurring in fewer than 1/1000 patients.</p>
<p><span class="Bold">General:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, heat sensitivity, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4137607" conceptname="Hangover">hangover effect</span>, and abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>. Rare were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, orthostatic effects, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.</p>
<p><span class="Bold">Atypical Sensations:</span> Frequent were warm/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensations.</p>
<p><span class="Bold">Cardiovascular:</span> Frequent was <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold extremities</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Rare was <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<p><span class="Bold">Digestive:</span> Frequent were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, acid <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>. Rare were <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, appetite increase, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> (tongue), and <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>.</p>
<p><span class="Bold">Metabolic:</span> Infrequent was <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p><span class="Bold">Musculoskeletal:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramp</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>. </p>
<p><span class="Bold">Neurological/Psychiatric:</span> Frequent were <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, mental acuity decreased, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, dream abnormality, gait abnormality, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>. Rare were: <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span>/<span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, and <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>.</p>
<p><span class="Bold">Respiratory:</span> Frequent was <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, irritation (nasal), congestion (nasal), <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, respiratory congestion (nasal), <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">dry nose</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and sinus disorder. Rare were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, and <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>.</p>
<p><span class="Bold">Special Senses:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, burning eye, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, and tearing. Rare were <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">smell perversion</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">photopsia</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> eye, and <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>.</p>
<p><span class="Bold">Skin and Skin Appendage:</span> Frequent was <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. Rare were <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="Bold">Urogenital System:</span> Frequent was <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, and menstruation disorder. Rare was <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>.</p>
<p>The adverse experience profile seen with MAXALT-MLT Orally Disintegrating Tablets was similar to that seen with MAXALT Tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54210643-45e3-4b19-813c-94f40b1e7b69"></a><a name="section-7.1"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">The following section enumerates potentially important adverse events that have occurred in clinical practice and which have been reported spontaneously to various surveillance systems. The events enumerated represent reports arising from both domestic and non-domestic use of rizatriptan. The events enumerated include all except those already listed in the ADVERSE REACTIONS section above or those too general to be informative. Because the reports cite events reported spontaneously from worldwide postmarketing experience, frequency of events and the role of rizatriptan in their causation cannot be reliably determined.</p>
<p><span class="Bold">Cardiovascular: </span> <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> (see <a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a>).</p>
<p><span class="Bold">Cerebrovascular:</span> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>.</p>
<p><span class="Bold">Neurological/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> (see <a href="#i4i_warnings_id_afc35c25-400c-4066-a9ff-4dacff93c6e8">WARNINGS</a>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span>.</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (e.g., facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, tongue <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>), <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_b09cd0c7-0e71-493b-9c9b-40a7ddfe3165"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Although the abuse potential of MAXALT has not been specifically assessed, no abuse of, tolerance to, withdrawal from, or drug-seeking behavior was observed in patients who received MAXALT in clinical trials or their extensions. The 5-HT<span class="Sub">1B/1D</span> agonists, as a class, have not been associated with drug abuse.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_9f209a88-5767-4225-a617-9242ba88b4d2"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of MAXALT were reported during clinical trials.</p>
<p>Rizatriptan 40 mg (administered as either a single dose or as two doses with a 2-hour interdose interval) was generally well tolerated in over 300 patients; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> were the most common drug-related adverse effects.</p>
<p>In a clinical pharmacology study in which 12 subjects received rizatriptan, at total cumulative doses of 80 mg (given within four hours), two subjects experienced <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. One subject, a female aged 29 years, developed <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> beginning three hours after receiving a total of 80 mg rizatriptan (administered over two hours); a <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span>, responsive to atropine, was observed an hour after the onset of the other symptoms. The second subject, a 25 year old male, experienced transient <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, and a 5-second systolic pause (on ECG monitor) immediately after a painful venipuncture. The venipuncture occurred two hours after the subject had received a total of 80 mg rizatriptan (administered over four hours).</p>
<p>In addition, based on the pharmacology of rizatriptan, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or other more serious cardiovascular symptoms could occur after overdosage. Gastrointestinal decontamination, (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with MAXALT. Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed.</p>
<p>The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5aa65e3b-f4cb-47ac-abca-65cf9d79fa26"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">In controlled clinical trials, single doses of 5 and 10 mg of MAXALT Tablets or MAXALT-MLT were effective for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> in adults. There is evidence that the 10-mg dose may provide a greater effect than the 5-mg dose (see <a href="#i4i_clinical_studies_id_53ad93f4-847e-43d7-9bfc-74aa3ebd856c">CLINICAL PHARMACOLOGY, Clinical Studies</a>). Individuals may vary in response to doses of MAXALT Tablets. The choice of dose should therefore be made on an individual basis, weighing the possible benefit of the 10-mg dose with the potential risk for increased adverse events.</p>
<p><span class="Italics">Redosing: </span> Doses should be separated by at least 2 hours; no more than 30 mg should be taken in any 24-hour period.</p>
<p>The safety of treating, on average, more than four <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in a 30-day period has not been established.</p>
<p><span class="Italics">Patients receiving propranolol:</span> In patients receiving propranolol, the 5-mg dose of MAXALT should be used, up to a maximum of 3 doses in any 24-hour period. (See <a href="#i4i_interactions_id_6844830e-902b-4e62-b431-e118c961e6c8">CLINICAL PHARMACOLOGY, Drug Interactions</a>.)</p>
<p>For MAXALT-MLT Orally Disintegrating Tablets, administration with liquid is not necessary. The orally disintegrating tablet is packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> within an outer aluminum pouch. Patients should be instructed not to remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the outer pouch until just prior to dosing. The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack should then be peeled open with dry hands and the orally disintegrating tablet placed on the tongue, where it will dissolve and be swallowed with the saliva.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ccaa4b29-c70f-4e05-871d-f666ebac6e9b"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">No. 3732 — MAXALT Tablets, 5 mg, are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> pink, capsule-shaped, compressed tablets coded MRK on one side and 266 on the other. They are supplied as follows:</p>
<p><span class="Bold">NDC </span> 0006-0266-18, carton of 18 tablets. </p>
<p>No. 3733 — MAXALT Tablets, 10 mg, are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> pink, capsule-shaped, compressed tablets coded MAXALT on one side and MRK 267 on the other. They are supplied as follows:</p>
<p><span class="Bold">NDC </span> 0006-0267-18, carton of 18 tablets.</p>
<p>No. 3800 — MAXALT-MLT Orally Disintegrating Tablets, 5 mg, are white to off-white, round lyophilized orally disintegrating tablets debossed with a modified triangle on one side, and measuring 10.0-11.5 mm (side-to-side) with a peppermint flavor. Each orally disintegrating tablet is individually packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> inside an aluminum pouch (sachet). They are supplied as follows:</p>
<p><span class="Bold">NDC </span> 0006-3800-18, 6 x unit of use carrying case of 3 orally disintegrating tablets (18 tablets total).</p>
<p>No. 3801 — MAXALT-MLT Orally Disintegrating Tablets, 10 mg, are white to off-white, round lyophilized orally disintegrating tablets debossed with a modified square on one side, and measuring 12.0-13.8 mm (side-to-side) with a peppermint flavor. Each orally disintegrating tablet is individually packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> inside an aluminum pouch (sachet). They are supplied as follows:</p>
<p><span class="Bold">NDC </span> 0006-3801-18, 6 x unit of use carrying case of 3 orally disintegrating tablets (18 tablets total).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_d49fd8b5-b478-401e-9821-a7abd12eeab9"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store MAXALT Tablets at room temperature, 15-30°C (59-86°F). Dispense in a tight container, if product is subdivided.</p>
<p>Store MAXALT-MLT Orally Disintegrating Tablets at room temperature, 15-30°C (59-86°F). The patient should be instructed not to remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the outer aluminum pouch until the patient is ready to consume the orally disintegrating tablet inside.</p>
<p><br>MAXALT Tablets are manufactured for:<br>Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>By:<br>MSD, Ltd.<br>Cramlington, Northumberland, NE23 3JU, UK</p>
<p><br>MAXALT-MLT Orally Disintegrating Tablets are manufactured for:<br>Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>By:<br>Catalent UK Swindon, Zydis Ltd.<br>Swindon, Wiltshire, SN5 8RU, UK</p>
<p>US Patent No.: 5,298,520</p>
<p>Issued August 2010</p>
<p>9652508</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_4ab8ff74-3f55-4cf8-91b2-496663986002"></a><a name="section-12"></a><p></p>
<h1>PATIENT PACKAGE INSERT</h1>
<p class="First">Patient Information about<br><span class="Bold">MAXALT<span class="Sup">®</span> (max-awlt) and MAXALT-MLT<span class="Sup">®</span></span><br>for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span><br>Generic name: rizatriptan benzoate</p>
<p>Please read this information before you start taking MAXALT<a href="#footnote-1" class="Sup">1</a>. Also, read the leaflet each time you renew your prescription, just in case anything has changed. Remember, this leaflet does not take the place of careful discussions with your doctor. You and your doctor should discuss MAXALT when you start taking your medication and at regular checkups.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b673ba1-91a9-48ea-b596-8190168c041d"></a><a name="section-12.1"></a><p></p>
<h2>What is MAXALT and what is it used for?</h2>
<p class="First">MAXALT is a medication used for the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in adults. MAXALT is a member of a class of drugs called selective 5-HT<span class="Sub">1B/1D</span> receptor agonists.</p>
<p>It is available as a traditional tablet (MAXALT) and as an orally disintegrating tablet (MAXALT-MLT<a href="#footnote-1" class="Sup">1</a>). Unless otherwise stated, the information contained in this leaflet applies both to MAXALT Tablets and to MAXALT-MLT Orally Disintegrating Tablets.</p>
<p>Tell your doctor about your symptoms. Your doctor will decide if you have <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. Use MAXALT only for a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. MAXALT should not be used to treat <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> that might be caused by other, more serious conditions.</p>
<p>You will find more information about <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> at the end of this leaflet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da700ad5-346a-4201-982b-fc045f189c32"></a><a name="section-12.2"></a><p></p>
<h2>How should I take MAXALT?</h2>
<p class="First">Your doctor has prescribed either a 5-mg or 10-mg dosage of MAXALT or MAXALT-MLT for your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. When you have a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>, take your medication as directed by your doctor.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad0d11ed-e2b0-45be-bb83-564facafeb0a"></a><a name="section-12.2.1"></a><p></p>
<h3><span class="Bold">MAXALT Tablets</span></h3>
<p class="First">If you are using MAXALT Tablets, swallow the tablet whole with liquid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c22faa08-42f2-467e-83e4-56375b77bc32"></a><a name="section-12.2.2"></a><p></p>
<h3><span class="Bold">MAXALT-MLT Orally Disintegrating Tablets </span></h3>
<p class="First">If you are using MAXALT-MLT, leave the orally disintegrating tablet in its package until you are ready to take it. Remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the foil pouch. Do not push the tablet through the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>; rather, peel open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack with dry hands and place the tablet on your tongue. The tablet will dissolve rapidly and be swallowed with your saliva. No liquid is needed to take the orally disintegrating tablet.</p>
<p>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back after your initial dose, a second dose may be taken anytime after 2 hours of administering the first dose. For any attack where you have no response to the first dose, do not take a second dose without first consulting with your doctor. Do not take more than 30 mg of MAXALT in a 24-hour period (for example, do not take more than three 10-mg tablets in a 24-hour period).</p>
<p>If you are receiving propranolol, you should use the 5-mg dose of MAXALT or MAXALT-MLT, up to a maximum of 3 doses (15 mg total) in a 24-hour period.</p>
<p>If your condition worsens, seek medical attention.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_03e3b5ea-41bc-402e-aa13-20e9c831a33d"></a><a name="section-12.3"></a><p></p>
<h2>Who should not take MAXALT?</h2>
<p class="First">Do not take MAXALT if you:</p>
<ul>
<li>have had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to MAXALT or any of its ingredients</li>
<li>have uncontrolled high blood pressure</li>
<li>have heart disease or history of heart disease</li>
<li>are currently taking monoamine oxidase (MAO) inhibitors<a name="footnote-reference-4" href="#footnote-4" class="Sup">2</a> such as phenelzine sulfate (NARDIL<span class="Sup">®</span>) or tranylcypromine sulfate (PARNATE<span class="Sup">®</span>) for mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or have taken MAO inhibitors within the last two weeks.</li>
</ul>
<p>MAXALT should not be used within 24 hours of treatment with another 5-HT<span class="Sub">1</span> agonist<a href="#footnote-4" class="Sup">2</a> such as sumatriptan (IMITREX<span class="Sup">®</span>), naratriptan (AMERGE<span class="Sup">™</span>) or zolmitriptan (ZOMIG<span class="Sup">™</span>); or ergotamine-type medications such as ergotamine (BELLERGAL-S<span class="Sup">®</span>, CAFERGOT<span class="Sup">®</span>, ERGOMAR<span class="Sup">®</span>, WIGRAINE<span class="Sup">®</span>), dihydro-ergotamine (D.H.E. 45<span class="Sup">®</span>), or methysergide (SANSERT<span class="Sup">®</span>).      </p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">2</a></dt>
<dd><p class="First">The brands listed are the trademarks of their respective owners and are not trademarks of Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span></p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c46965c7-c994-4916-8597-0da3ff27d439"></a><a name="section-12.4"></a><p></p>
<h2>What should I tell my doctor before and during treatment with MAXALT?</h2>
<p class="First">Tell your doctor:</p>
<ul>
<li>about any past or present medical problems<br>
</li>
<li>about any history of high blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, heart disease, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span><br>
</li>
<li>about any risk factors for heart disease or blood vessel disease <ul>
<li>high blood pressure or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span></li>
<li>smoking</li>
<li>family history of heart disease or blood vessel disease</li>
<li>post menopausal</li>
<li>male over 40</li>
</ul>
</li>
<li>about any allergies you have or have had<br>
</li>
<li>if you are pregnant or plan to become pregnant<br>
</li>
<li>if you are breast-feeding or plan to breast-feed<br>
</li>
<li>about all drugs you are taking or plan to take, including those obtained without a prescription, and those you normally take for a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.<br>
</li>
<li>if you take selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), two types of drugs for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other disorders. Common SSRIs<a href="#footnote-4" class="Sup">2</a> are CELEXA<span class="Sup">®</span> (citalopram HBr), LEXAPRO<span class="Sup">®</span> (escitalopram oxalate), PAXIL<span class="Sup">®</span> (paroxetine), PROZAC<span class="Sup">®</span>/SARAFEM<span class="Sup">®</span>(fluoxetine), SYMBYAX<span class="Sup">®</span> (olanzapine/fluoxetine), ZOLOFT<span class="Sup">®</span> (sertraline), and fluvoxamine. Common SNRIs<a href="#footnote-4" class="Sup">2</a> are CYMBALTA<span class="Sup">®</span> (duloxetine) and EFFEXOR<span class="Sup">®</span> (venlafaxine).</li>
</ul>
<p><span class="Bold">MAXALT-MLT orally disintegrating tablets contain aspartame, a source of phenylalanine.</span></p>
<p>Phenylketonurics: MAXALT-MLT 5-mg and 10-mg orally disintegrating tablets contain 1.05 and 2.10 mg phenylalanine, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba6a982e-0be5-4be0-9610-d0ce59f5c2a4"></a><a name="section-12.5"></a><p></p>
<h2>What if I am pregnant?</h2>
<p class="First">Do not use MAXALT if you are pregnant, think you might be pregnant, are trying to become pregnant, or are not using adequate contraception, unless you have discussed this with your doctor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d097760f-37d6-44cd-a3a4-90d3a9945449"></a><a name="section-12.6"></a><p></p>
<h2>Can I take MAXALT with other medications<a href="#footnote-4" class="Sup">2</a>?</h2>
<p class="First">Do not take MAXALT with any other drug in the same class within 24 hours, such as sumatriptan (IMITREX<span class="Sup">®</span>), naratriptan (AMERGE<span class="Sup">™</span>) or zolmitriptan (ZOMIG<span class="Sup">™</span>).</p>
<p>Do not take MAXALT within 24 hours of taking ergotamine-type medications such as ergotamine (BELLERGAL-S<span class="Sup">®</span>, CAFERGOT<span class="Sup">®</span>, ERGOMAR<span class="Sup">®</span>, WIGRAINE<span class="Sup">®</span>), dihydro-ergotamine (D.H.E. 45<span class="Sup">®</span>) or methysergide (SANSERT<span class="Sup">®</span>) to treat your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
<p>Do not take MAXALT when you are taking monoamine oxidase (MAO) inhibitors, such as phenelzine sulfate (NARDIL<span class="Sup">®</span>) or tranylcypromine sulfate (PARNATE<span class="Sup">®</span>) for mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or if it has been less than two weeks since you stopped taking an MAO inhibitor.</p>
<p>Ask your doctor for instructions about taking MAXALT if you are now taking propranolol (INDERAL<span class="Sup">®</span>). (See <a href="#i4i_section_id_da700ad5-346a-4201-982b-fc045f189c32">How should I take MAXALT?</a> section.)</p>
<p>Ask your doctor for instructions about taking MAXALT if you are now taking selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), two types of drugs for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other disorders. (See <a href="#i4i_section_id_c46965c7-c994-4916-8597-0da3ff27d439">What should I tell my doctor before and during treatment with MAXALT?</a> section.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f2a673b-f286-44a1-a6a1-6a7c42f0f976"></a><a name="section-12.7"></a><p></p>
<h2>What are the possible side effects of MAXALT? </h2>
<p class="First">Like all prescription drugs, MAXALT can cause side effects. In studies, MAXALT was generally well-tolerated. The side effects were usually mild and temporary. The following is <span class="Bold">not</span> a complete list of side effects reported with MAXALT. Do not rely on this leaflet alone for information about side effects. Ask your doctor to discuss with you the more complete list of side effects.</p>
<p>In studies, the <span class="Bold">most common</span> side effects reported were:</p>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> </span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or pressure sensation (e.g., in the chest or throat)</span></li>
</ul>
<p>If you experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, you should evaluate your ability to perform complex tasks such as driving or operating heavy machinery.</p>
<p>Other, <span class="Bold">less common</span> side effects reported in studies or general use were related to the:</p>
<p><span class="Bold">Heart and blood vessels -</span> Alterations in heartbeat, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and spasm of blood vessels of the extremities including <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of the hands or feet.</p>
<p><span class="Bold">Muscles -</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, and spasm; and muscle and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>.</p>
<p><span class="Bold">Nervous system -</span> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, decreased mental sharpness, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, abnormal sensation, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>, mood and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, alterations in speech and movement, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, dream abnormality and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</p>
<p><span class="Bold">Digestive system -</span> <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach upset</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, gas, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, acid reflux, difficulty swallowing, changes in appetite, burping and inability of the tongue to move.</p>
<p><span class="Bold">Skin -</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the face lasting a short time), <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> to sunlight.</p>
<p><span class="Bold">Respiratory -</span> Difficult or rapid breathing, dryness or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> of the throat or nose, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nosebleed</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span> and sinus disorder, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>. </p>
<p><span class="Bold">Special Senses -</span> <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span>, ringing in the ears, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, eye <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or tearing, alterations in hearing and smelling, visual intolerance to light, and bad taste.</p>
<p><span class="Bold">Miscellaneous -</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, lips, tongue and/or throat which may cause difficulty in breathing and/or swallowing, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and severe <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> of the skin. Also <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, heat sensitivity, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, <span class="product-label-link" type="condition" conceptid="4137607" conceptname="Hangover">hangover effect</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> on standing up, warm/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensations, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and changes in urination and menstruation.</p>
<p>As with other drugs in this class, there have been very rare reports of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> generally occurring in patients with risk factors for heart and blood vessel disease (see <a href="#i4i_section_id_c46965c7-c994-4916-8597-0da3ff27d439">What should I tell my doctor before and during treatment with MAXALT?</a>).</p>
<p>Tell your doctor about these or any other symptoms. If the symptoms persist or worsen, seek medical attention promptly. In addition, tell your doctor if you experience any symptoms that suggest an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (see <span class="Bold">Miscellaneous</span> above) after taking MAXALT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab18b28c-4b35-4873-b748-6c3789c4d1f4"></a><a name="section-12.8"></a><p></p>
<h2>What should I do if I take an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>?</h2>
<p class="First">If you take more medication than you have been told to take, you should contact your doctor, hospital emergency department, or nearest poison control center immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2024f57f-0609-4c86-9464-95ef7be02c0b"></a><a name="section-12.9"></a><p></p>
<h2>What is <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> and how does it differ from other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>?</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> is an intense, throbbing, typically one-sided <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> that often includes <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sensitivity to light, and sensitivity to sound. According to many <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> sufferers, the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and symptoms from a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> are more intense than the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and symptoms of a common <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Some people may have visual symptoms before the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, such as <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">flashing lights</span> or wavy lines, called an <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> attacks typically last for hours or, rarely, for more than a day, and they can return frequently. The severity and frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks may vary.</p>
<p>Based on your symptoms, your doctor will decide whether you have <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6dee677-01c2-421c-856e-3aca36a18b66"></a><a name="section-12.10"></a><p></p>
<h2>Who gets <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>?</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine headaches</span> tend to occur in members of the same family. Both men and women get <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, but it is more common in women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35b18986-169b-40aa-8f5f-4ae5ace0293d"></a><a name="section-12.11"></a><p></p>
<h2>What may trigger a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack?</h2>
<p class="First">Certain things are thought to trigger <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in some people. Some of these triggers are:</p>
<ul>
<li>certain foods or beverages (e.g., cheese, chocolate, citrus fruit, caffeine, alcohol)</li>
<li>stress</li>
<li>change in a behavior (e.g., under/oversleeping; missing a meal; change in diet)</li>
<li>hormonal changes in women (e.g., menstruation)</li>
</ul>
<p>You may be able to prevent <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks or diminish their frequency if you understand what specifically triggers your attacks. Keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary may help you identify and monitor the possible <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> triggers you encounter. Once the triggers are identified, you and your doctor can modify your treatment and lifestyle appropriately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97547319-b022-4b1a-99ce-098f5cd4ebbf"></a><a name="section-12.12"></a><p></p>
<h2>How does MAXALT work during a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack? </h2>
<p class="First">Treatment with MAXALT:</p>
<ol>
<li>Reduces <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of blood vessels surrounding the brain. This <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> results in the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack.<br>
</li>
<li>Blocks the release of substances from nerve endings that cause more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and other symptoms of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.<br>
</li>
<li>Interrupts the sending of specific <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> signals to your brain.</li>
</ol>
<p>It is thought that each of these actions contributes to relief of your symptoms by MAXALT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0c0e618-11e9-4f6d-b264-368e9c3e9bb3"></a><a name="section-12.13"></a><p></p>
<h2>How should I store MAXALT?</h2>
<p class="First">Keep your medicine in a safe place where children cannot reach it. It may be harmful to children. Store your medication away from heat, light, moisture, and at a controlled room temperature 59°-86°F (15°-30°C). If your medication has expired, throw it away as instructed. If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to do so. Throw away your medicine as instructed. Be sure that the discarded tablets are out of the reach of children.</p>
<p>If you are storing MAXALT-MLT, do not remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the outer aluminum pouch until you are ready to take the medication inside.</p>
<p>This leaflet provides a summary of information about MAXALT. If you have any questions or concerns about either MAXALT or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, talk to your doctor. In addition, talk to your pharmacist or other health care provider.</p>
<p><br>MAXALT Tablets are manufactured for:<br>Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>By:<br>MSD, Ltd.<br>Cramlington, Northumberland, NE23 3JU, UK</p>
<p><br>MAXALT-MLT Orally Disintegrating Tablets are manufactured for:<br>Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>By:<br>Catalent UK Swindon, Zydis Ltd.<br>Swindon, Wiltshire, SN5 8RU, UK</p>
<p>US Patent No.: 5,298,520</p>
<p>Issued August 2010</p>
<p>9652508</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PACKAGE LABEL - MAXALT-MLT - 5MG - 12 TABS</h1>
<p class="First">Maxalt-MLT<span class="Sup">®</span><br>(rizatriptan benzoate)</p>
<p>5 mg</p>
<p>ORALLY DISINTEGRATING TABLETS</p>
<p>Each tablet contains 14.53 mg of rizatriptan benzoate, equivalent to 5 mg 
rizatriptan.</p>USUAL ADULT DOSAGE: See accompanying circular.<p>Rx only</p>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08d06e6f-a1d8-4bd9-b851-d63858d55f91&amp;name=MAXALT-MLT%205MG%20144.jpg"></div>
<br><br><p><br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PACKAGE LABEL - MAXALT - 10 MG - 18 TABS</h1>        <br><p class="First">Maxalt<span class="Sup">®</span><br>(rizatriptan benzoate)</p>
<p>10 mg</p>
<p>TABLETS</p>
<p>Each tablet contains 14.53 mg of rizatriptan benzoate, equivalent to 10 mg 
rizatriptan.</p>
<p>18 Tablets</p>
<p>USUAL ADULT DOSAGE: See accompanying circular.</p>
<p>Rx only</p>                                        <div class="Figure"><img alt="Label Image 10mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08d06e6f-a1d8-4bd9-b851-d63858d55f91&amp;name=MAXALT%2010MG%20LABEL%20461.jpg"></div>
<br><br><p><br></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAXALT-MLT 		
					</strong><br><span class="contentTableReg">rizatriptan benzoate tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-144(NDC:0006-3800)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIZATRIPTAN BENZOATE</strong> (RIZATRIPTAN) </td>
<td class="formItem">RIZATRIPTAN BENZOATE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">PEPPERMINT (PEPPERMINT) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-144-12</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020865</td>
<td class="formItem">06/29/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAXALT 		
					</strong><br><span class="contentTableReg">rizatriptan benzoate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-461(NDC:0006-0267)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIZATRIPTAN BENZOATE</strong> (RIZATRIPTAN) </td>
<td class="formItem">RIZATRIPTAN BENZOATE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">PALE</span> PINK) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (CAPSULE SHAPED) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MAXALT;MRK;267</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-461-18</td>
<td class="formItem">18  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020864</td>
<td class="formItem">06/29/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT RX USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>59644bee-0419-41bc-8b33-4608064096c0</div>
<div>Set id: 08d06e6f-a1d8-4bd9-b851-d63858d55f91</div>
<div>Version: 2</div>
<div>Effective Time: 20110822</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
